Hostname: page-component-6766d58669-88psn Total loading time: 0 Render date: 2026-05-20T09:14:55.978Z Has data issue: false hasContentIssue false

Biofilms in chronic rhinosinusitis: what is new and where next?

Published online by Cambridge University Press:  29 June 2015

Y Ramakrishnan*
Affiliation:
Department of Otolaryngology, Freeman Hospital, Newcastle upon Tyne, UK
R C Shields
Affiliation:
School of Dental Sciences, Newcastle University, UK
M R Elbadawey
Affiliation:
Department of Otolaryngology, Freeman Hospital, Newcastle upon Tyne, UK Department of Otolaryngology, Tanta University, Egypt
J A Wilson
Affiliation:
Department of Otolaryngology, Freeman Hospital, Newcastle upon Tyne, UK
*
Address for correspondence: Dr Yujay Ramakrishnan, Department of Otolaryngology, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK E-mail: yujay.ramakrishnan@gmail.com

Abstract

Background:

Chronic rhinosinusitis is a common, heterogeneous condition. An effective means of mitigating disease in chronic rhinosinusitis patients remains elusive. A variety of causes have been implicated, with the biofilm theory gaining increasing prominence.

Objective:

This article reviews the literature on the role of biofilms in chronic rhinosinusitis, in terms of pathophysiology and with regard to avenues for future treatment.

Methods:

A systematic review of case series was performed using databases with independently developed search strategies, including Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane library, and Zetoc, in addition to conference proceedings and a manual search of literature, with the last search conducted on 18 January 2014. The search terms included the following, used in various combinations to maximise the yield of articles identified: ‘biofilms’, ‘chronic rhinosinusitis’, ‘DNase’, ‘extracellular DNA’ and ‘biofilm dispersal’.

Results:

The existing evidence lends further support for the role of biofilms (particularly the Staphylococcus aureus phenotype) in more severe, recalcitrant disease and poorer surgical outcomes.

Conclusion:

Multimodality treatment, with a shift in paradigm to incorporate anti-biofilm strategies, is likely to form the mainstay of future recalcitrant chronic rhinosinusitis management.

Information

Type
Review Articles
Copyright
Copyright © JLO (1984) Limited 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable